Acri, J.B., Brown, K.J., Saah, M.I. and Grunberg, N.E. (1995) “Strain and age differences in acoustic startle responses and effects of nicotine in rats”, Pharmacol. Biochem. Behav.
Allen, A.R., Singh, A., Zhuang, Z.P., Kung, M.P., Kung, H.F. and Lucki, I. (1997) “The 5-HT1A
receptor antagonist p-MPPI blocks responses mediated by postsynaptic and presynaptic 5-HT1A
receptors”, Pharmacol. Biochem. Behav.
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders IV (American Psychiatric Press, Washington DC).
Angrist, B., Rotrosen, J. and Gershon, S. (1980) “Differential effects of amphetamine and neuroleptics on negative and positive symptoms in schizophrenia”, Psychopharmacology
Angrist, B., Peselow, E., Rubenstein, M., Corwin, J. and Rotrosen, J. (1982) “Partial improvement in negative schizophrenic symptoms after amphetamine”, Psychopharmacology
Ascher, J.A., Cole, J.O., Colin, J.-N., Feighner, J.P., Ferris, R.M., Fibiger, H.C., Golden, R.N., Martin, P., Potter, W.Z., Richelson, E. and Sulser, F. (1995) “Bupropion: a review of its mechanisms of antidepressant activity”, J. Clin. Pharmacol.
Aubin, H.J., Tilikete, S. and Barrucand, D. (1996) “Depression and smoking”, Encephale
Baker, G.B. and Greenshaw, A.J. (1989) “Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system”, Cell. Mol. Neurobiol.
Baldo, B.A., Koob, G.F. and Markou, A. (1999) “Role of adenosine A2 receptors in brain stimulation reward under baseline conditions and during cocaine withdrawal in rats”, J. Neurosci.
Binder, R.L., Kazamatsuri H., Nishimura, T. and McNiel, D.E. (1987) “Smoking and tardive dyskinesia”, Biol. Psychiatry
Blier, P. and de Montigny, C. (1994) “Current advances and trends in the treatment of depression”, Trends Pharmacol. Sci.
Bokstrom, K. and Balldin, J. (1992) “A rating scale for assessment of alcohol withdrawal psychopathology (AWIP)”, Alcohol Clin. Exp. Res.
Borowski, T.B. and Kokkinidis, L. (1992) “Long-term influence of d-amphetamine on mesolimbic brain-stimulation reward: comparison to chronic haloperidol and naloxone effects”, Pharmacol. Biochem. Behav.
Breslau, N., Kilbey, M.M. and Andreski, P. (1993) “Nicotine dependence and major depression: New evidence from a prospective investigation”, Arch. Gen. Psychiatry
Breslau, N., Peterson, E.L., Schultz, L.R., Chilcoat, H.D. and Andreski, P. (1998) “Major depression and stages of smoking. A longitudinal investigation”, Arch. Gen. Psychiatry
Buckley, P., Thompson, P., Way, L. and Meltzer, H.Y. (1994) “Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy”, Am. J. Psychiatry
Caldecott-Hazard, S. and Schneider, L.S. (1992) “Clinical and biochemical aspects of depressive disorders: III. Treatment and controversies”, Synapse
Carboni, E., Bortone, L., Giua, C. and DiChiara, G. (2000) “Dissociation of physical abstinence signs from changes in extracellular dopamine in the nucleus accumbens and in the prefrontal cortex of nicotine dependent rats”, Drug Alcohol Depend.
Carton, S., Jouvent, R. and Widlocher, D. (1994) “Nicotine dependence and motives for smoking in depression”, J. Subst. Abuse
Carton, S., Le Houezec, J., Lagrue, G. and Jouvent, R. (2000) “Relationships between sensation seeking and emotional symptomatology during smoking cessation with nicotine patch therapy”, Addict. Behav.
Cassens, G., Actor, C., Kling, M. and Schildkraut, J.J. (1981) “Amphetamine withdrawal: effects on threshold of intracranial reinforcement”, Psychopharmacology
Cesarec, Z. and Nyman, A.K. (1985) “Differential response to amphetamine in schizophrenia”, Acta Psychiatr. Scand.
Claghorn, J., Honigfeld, G., Abuzzahab, F.S., Wang, R., Steinbook, R., Tuason, V. and Klerman, G. (1987), “The risks and benefits of clozapine versus chloropromazine”, J. Clin. Psychopharmacol.
Corrigall, W.A. and Coen, K.M. (1991) “Selective dopamine antagonists reduce nicotine self-administration”, Psychopharmacology
Cuffel, B.J. (1992) “Prevalence estimates of substance abuse in schizophrenia and their correlates”, J. Nerv. Ment. Dis.
Curzon, P., Kim, D.J. and Decker, M.W. (1994) “Effect of nicotine, lobeline, and mecamylamine on sensory gating in the rat”, Pharmacol. Biochem. Behav.
Dalack, G.W., Glassman, A.H., Rivelli, S., Covey, L. and Stetner, F. (1995) “Mood, major depression, and fluoxentine response in cigarette smokers”, Am. J. Psychiatry
Dalack, G.W., Healy, D.J. and Meador-Woodruff, J.H. (1998) “Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings”, Am. J. Psychiatry
Dalack, G.W., Becks, L., Hill, E., Pomerleau, O.F. and Meador-Woodruff, J.H. (1999) “Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia”, Neuropsychopharmacology
Decina, P., Caracci, G., Sandik, R., Berman, W., Mukherjee, S. and Scapicchio, P. (1990) “Cigarette smoking and neuroleptic-induced parkinsonism”, Biol. Psychiatry
Desai, N.G., Gangadhar, B.N., Pradhan, N. and Channabasavanna, S.M. (1984) “Treatment of negative schizophrenia with d-amphetamine.” Am. J. Psychiatry
Diwan, A., Castine, M., Pomerleau, C.S., Meador-Woodruff, J.H. and Dalack, G.W. (1998) “Differential prevalence of cigarette smoking in patients with schizophrenic vs mood disorders”, Schizophr. Res.
Dixon, L., Haas, G., Weiden, P., Sweeney, J. and Frances, A. (1990) “Acute effects of drug abuse in schizophrenic patients: clinical observations and patients' self-reports”, Schizophr. Bull.
Dixon, L., Haas, G., Weiden, P., Sweeney, J. and Frances, A.J. (1991) “Drug abuse in schizophrenic patients: clinical correlates and reasons for use”, Am. J. Psychiatry
Edwards, G. (1990) “Withdrawal symptoms and alcohol dependence: fruitful mysteries”, Br. J. Addict.
El Yacoubi, M., Ledent, C., Parmentier, M., Bertorelli, R., Ongini, E., Costentin, J. and Vaugeois, J.-M. (2001) “Adenosine A2A
receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A
receptor knockout mice”, Br. J. Pharmacol.
Ellenbroek, B.A. and Cools, A.R. (2000) “Animal models for the negative symptoms of schizophrenia”, Behav. Pharmacol.
Epping-Jordan, M.P., Watkins, S.S., Koob, G.F. and Markou, A. (1998) “Dramatic decreases in brain reward function during nicotine withdrawal”, Nature
Esposito, R.U. and Kornetsky, C. (1977) “Morphine lowering of self-stimulation thresholds: lack of tolerance with long-term administration”, Science
Fechner, G.T. (1966) In: Adler, H.E., Howes, D.H. and Boring, E.G., translators Elements of Psychophysics (Holt, Rinehart and Winston, New York) Vol. 1.
Feighner, J.P., Meredith, C.H., Stern, W.C., Hendrickson, G. and Miller, L.L. (1984) “A double-blind study of bupropion and placebo in depression”, Am. J. Psychiatry
Ferry, L.H. and Burchette, R.J. (1994) Evalution of Buproprion Versus Placebo for Treatment of Nicotine Dependence (American Psychiatric Association New Research, Washington DC), pp 199–200.
Frank, R.A., Manderscheid, P.Z., Panicker, S., Williams, H.P. and Kokoris, D. (1992) “Cocaine euphoria, dysphoria, and tolerance assessed using drug-induced changes in brain-stimulation reward”, Pharmacol. Biochem. Behav.
Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., Polymeropoulos, M., Holik, J., Hopkins, J., Hoff, M., Rosenthal, J., Waldo, M.C., Reimherr, F., Wender, P., Yaw, J., Young, D.A., Breese, C.R., Adams, C., Patterson, D., Adler, L.E., Kruglyak, L., Leonard, S. and Byerley, W. (1997) “Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus”, Proc. Natl Acad. Sci. USA
Fryer, J.D. and Lukas, R.J. (1999) “Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine”, J. Pharmacol. Exp. Ther.
Fudala, P.J., Teoh, K.W. and Iwamoto, E.T. (1985) “Pharmacologic characterization of nicotine-induced conditioned place preference”, Pharmacol. Biochem. Behav.
Gawin, F.H. and Kleber, H.D. (1986) “Abstinence symptomatology and psychiatric diagnosis in cocaine abusers: clinical observations”, Arch. Gen. Psychiatry
George, T.P., Sernyak, M.J., Ziedonis, D.M. and Woods, S.W. (1995) “Effects of clozapine on smoking in chronic schizophrenic outpatients”, J. Clin. Psychiatry
Geyer, M.A. and Braff, D.L. (1987) “Startle habituation and sensorimotor gating in schizophrenia and related animal models”, Schizophr. Bull.
Geyer, M.A. and Markou, A. (1995) “Animal models of psychiatric disorders”, In: Bloom, F.E. and Kupfer, D.J., eds, Psychopharmacology: The Fourth Generation of Progress (Raven Press, New York), pp 787–798.
Geyer, M.A. and Markou, A. (2002) “The role of preclinical models in the development of psychotropic drugs”, In: Charney, D., Coyle, J., Davis, K. and Nemeroff, C., eds, Psychopharmacology: The Fifth Generation of Progress (Lippincott/Williams and Wilkins, Philadelphia/Baltimore), pp. 445–455.
Glassman, A.H. (1993) “Cigarette smoking: implications for psychiatric illness”, Am. J. Psychiatry
Glassman, A.H., Stetner, F. and Walsh, B.T. (1988) “Heavy smokers, smoking cessation and clonidine: results of a double-blind, randomized trial”, J. Am. Med. Assoc.
Glassman, A.H., Helzer, J.E., Covey, L.S., Cottler, L.B., Stetner, F., Tipp, J.E. and Johnson, J. (1990) “Smoking, smoking cessation, and major depression”, J. Am. Med. Assoc.
Glowinski, J. and Axelrod, J., (1964) “Inhibition of uptake of tritiated-noradrenaline in the intact rat brain by imipramine and structurally related compounds”, Science
Glynn, S.M. and Sussman, S. (1990) “Why patients smoke”, Hosp. Community Psychiatry
Goff, D.C., Henderson, D.C. and Amico, E. (1992) “Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects”, Am. J. Psychiatry
Goldberg, S.R. and Henningfield, J.E. (1988) “Reinforcing effects of nicotine in humans and experimental animals responding under intermittent schedules of i.v. drug injection”, Pharmacol. Biochem. Behav.
Goldberg, S.R., Spealman, R.D. and Goldberg, D.M. (1981) “Persistent behavior at high rates maintained by intravenous self-administration of nicotine”, Science
Goodwin, D.W. (1992) “Alcohol: clinical aspects”, In: Lowinson, J.H., Ruiz, P., Millman, R.B. and Langrod, J.G., eds, Substance Abuse: A Comprehensive Textbook (Williams and Wilkins, Baltimore, MD), pp. 144–151.
Gosling, J.A. and Lu, T.C. (1969) “Uptake and distribution of some quaternary ammonium compounds in the central nervous system of the rat”, J. Pharmacol. Exp. Ther.
Green, A.R. (1987) “Evolving concepts on the interactions between antidepressant treatments and monoamine neurotransmitters”, Neuropharmacology
Green, A.I., Zimmet, S.V., Strous, R.D. and Schildkraut, J.J. (1999) “Clozapine for comorbid substance use disorder and schizophrenia: Do patients with schizophrenia have a rewarddeficiency syndrome that can be ameliorated by clozapine?”, Harvard Res. Psychiatry
Haertzen, C.A. and Hooks, Jr., N.T. (1969) “Changes in personality an subjective experience associated with the chronic administration and withdrawal of opiates”, J. Nerv. Ment. Dis.
Hall, R.G., Duhamel, M., McClanahan, R., Miles, G., Nason, C., Rosen, S., Schiller, P., Tao-Yonenaga, L. and Hall, S.M. (1995) “Level of functioning, severity of illness, and smoking status among chronic psychiatric patients”, J. Nerv. Ment. Dis.
Harrison, A.A., Liem, Y.T. and Markou, A. (2001) “Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats”, Neuropsychopharmacology
Henningfield, J.E. and Goldberg, S.R. (1983) “Nicotine as a reinforcer in human subjects and laboratory animals”, Pharmacol. Biochem. Behav.
Henningfield, J.E., Johnson, R.E. and Jasinski, D.R. (1987) “Clinical procedures for the assessment of abuse potential”, In: Bozarth, M.A., eds, Methods of Assessing the Reinforcing Properties of Abused Drugs (Springer, New York), pp 573–590.
Hildebrand, B.E., Nomikos, G.G., Bondjers, C., Nisell, M. and Svensson, T.H. (1997) “Behavioral manifestations of the nicotine abstinence syndrome in the rat: peripheral versus central mechanisms”, Psychopharmacology
Hildebrand, B.E., Panagis, G., Svensson, T.H. and Nomikos, G.G. (1999) “Behavioral and biochemical manifestations of mecamy-lamine-precipitated nicotine withdrawal in the rat: role of nicotinic receptors in the ventral tegmental area”, Neurosychopharmacology
Hughes, J.R. (1992) “Tobacco withdrawal in self-quitters”, J. Consult. Clin. Psychol.
Hughes, J.R. (1993) “Possible effects of smoke-free inpatient units on psychiatric diagnosis and treatment”, J. Clin. Psychiatry
Hughes, J.R. (1996) “The future of smoking cessation therapy in the United States”, Addiction
Hughes, J.R. and Hatsukami, D. (1992) “The nicotine withdrawal syndrome: a brief review and update”, Int. J. Smoking Cessation
Hughes, J.R., Hatsukami, D.K., Pickens, R.W., Krahn, D., Malin, S. and Luknic, A. (1984) “Effect of nicotine on the tobacco withdrawal syndrome”, Psychopharmacology
Hughes, J.R., Hatsukami, D.K., Mitchell, J.E. and Dahlgren, L.A. (1986) “Prevalence of smoking among psychiatric outpatients”, Am. J. Psychiatry
Hughes, J.R., Gust, S.W., Skoog, K., Keenan, R.M. and Fenwick, J.W. (1991) “Symptoms of tobacco withdrawal: a replication and extension”, Arch. Gen. Psychiatry
Hughes, J.R., Higgins, S.T. and Bickel, W.K. (1994) “Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities”, Addiction
Hurt, R.D., Sachs, D.P.L., Glover, E.D., Offord, K.P., Johnston, J.A., Dale, L.C., Khayrallah, M.A., Schroeder, D.R., Glover, P.N., Sullivan, C.R., Croghan, I.T. and Sullivan, P.M. (1997) “A comparison of sustained-release buproprion and placebo for smoking cessation”, N. Engl. J. Med.
Huston-Lyons, D. and Kornetsky, C. (1992) “Effects of nicotine on the threshold for rewarding brain stimulation in rats”, Pharmacol. Biochem. Behav.
Isola, R., Vogelsberg, V., Wemlinger, T.A., Neff, N.H. and Hadjiconstantinou M. (1999) “Nicotine abstinence in the mouse”, Brain Res.
Jaffe, J.H. (1990) “Drug addiction and drug abuse”, In: Goodman Gilman, A., Rall, T.W., Nies, A.S. and Taylor, P., eds, Goodman's and Gilman's The Pharmacological Basis of Therapeutics, 8th ed. (Pergamon Press, Elmsford, New York), pp 522–573.
Jarvik, M.E. (1991) “Beneficial effects of nicotine”, Br. J. Addict.
Jibson, M.D. and Tandon, R. (1998) “New atypical antipsychotic medications”, J. Psychiatr. Res.
Jorenby, D.E., Leischow, S.J., Nides, M.A., Rennard, S.I., Johnston, J.A., Hughes, A.R., Smith, S.S., Muramoto, M.L., Daughton, D.M., Doan, K., Fiore, M.C. and Baker, T.B. (1999) “A controlled trial of sustained-release buproprion, a nicotine patch, or both for smoking cessation”, N. Engl. J. Med.
van Kammen, D.P. and Boronow, J.J. (1988) “Dextro-amphetamine diminishes negative symptoms in schizophrenia”, Int. Clin. Psychopharmacol.
Kendler, K.S., Neale, M.C., MacLean, C.J., Heath, A.C., Eaves, L.J. and Kessler, R.C. (1993) “Smoking and major depression: a causal analysis”, Arch. Gen. Psychiatry
Kessler, R.C., McGonagle, K.A., Zhao, S., Nelson, C.B., Hughes, M., Eshleman, S., Wittchen, H.U. and Kendler, K.S. (1994) “Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey”, Arch. Gen. Psychiatry
Khantzian, E.J. (1985) “The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence”, Am. J. Psychiatry
Khantzian, E.J. (1997) “The self-medication hypothesis of substance use disorders: a reconsideration and recent applications”, Harv. Rev. Psychiatr.
Knights, A. and Hirsch, S.R. (1981) “Revealed' depression and drug treatment for schizophrenia”, Arch. Gen. Psychiatry
Kokkinidis, L. and McCarter, B.D. (1990) “Postcocaine depression and sensitization of brain stimulation reward: analysis of reinforcement and performance effects”, Pharmacol. Biochem. Behav.
Kokkinidis, L. and Zacharko, R.M. (1980a) “Enhanced lateral hypothalamic self-stimulation responding after chronic exposure to amphetamine”, Behav. Neural Biol.
Kokkinidis, L. and Zacharko, R.M. (1980b) “Response sensitization and depression following long-term amphetamine treatment in a self-stimulation paradigm”, Psychopharmacology
Kokkinidis, L., Zacharko, R.M. and Predy, P.A. (1980) “Postamphetamine depression of self-stimulation responding from the substantia nigra: reversal by tricyclic antidepressants”, Pharmacol. Biochem. Behav.
Kokkinidis, L., Zacharko, R.M. and Anisman, H. (1986) “Amphetamine withdrawal: a behavioral evaluation”, Life Sci.
Koob, G.F., Markou, A., Weiss, F. and Schulteis, G. (1993) “Opponent process and drug dependence: Neurobiological mechanisms”, Semin. Neurosci.
Kornetsky, C. and Esposito, R.U. (1981) “Reward and detection thresholds for brain stimulation: dissociative effects of cocaine”, Brain Res.
Kornetsky, C., Markowitz, R.A. and Esposito, R.U. (1981) “Phencyclidine and naloxone: effects on sensitivity to aversive and rewarding stimulation in the rat”, In: Domino, E.F., eds, PCP (Phencyclidine): Historical and Current Perspectives (NPP Books, Ann Arbor), pp 321–330.
Krystal, J.H., D'Souza, D.C., Madonick, S. and Petrakis, I.L. (1999) “Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients”, Schizophr. Res.
Kumari, V., Checkley, S.A. and Gray, J.A. (1996) “Effect of cigarette smoking on prepulse inhibition of the acoustic startle reflex in healthy male smokers”, Psychopharmacology
LeDuc, P.A. and Mittleman, G. (1995) “Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence”, Psychopharmacology
Leith, N.J. and Barrett, R.J. (1976) “Amphetamine and the reward system: evidence for tolerance and post-drug depression”, Psychopharmacologia
Leith, N.J. and Barrett, R.J. (1980) “Effects of chronic amphetamine or reserpine on self-stimulation responding: animal model of depression?”, Psychopharmacology
de Leon, J., Dadvand, M., Canuso, C., White, A.O., Stanilla, J.K. and Simpson, G.M. (1995) “Schizophrenia and smoking: and epidemiological survey in a state hospital”, Am. J. Psychiatry
Lin, D., Koob, G.F. and Markou, A. (1999) “Differential effects of withdrawal from chronic amphetamine or fluoxetine administration on brain stimulation reward in the rat: Interactions between the two drugs”, Psychopharmacology
Lysaker, P., Bell, M., Beam-Goulet, J. and Milstein, R. (1994) “Relationship of positive and negative symptoms to cocaine abuse in schizophrenia”, J. Nerv. Ment. Dis.
Malin, D.H., Lake, J.R., Newlin-Maultsby, P., Roberts, L.K., Lanier, J.G., Carter, V.A., Cunningham, J.S. and Wilson, O.B. (1992) “Rodent model of nicotine abstinence syndrome”, Pharmacol. Biochem. Behav.
Malin, D.H., Lake, J.R., Carter, V.A., Cunningham, J.S., Hebert, K.M., Conrad, D.L. and Wilson, O.B. (1994) “The nicotinic antagonist mecamylamine precipitates nicotine abstinence syndrome in the rat”, Psychopharmacology
Malin, D.H., Lake, J.R., Schopen, C.K., Kirk, J.W., Sailer, E.E., Lawless, B.A., Upchurch, T.P., Shenoi, M. and Rajan, N. (1997) “Nicotine abstinence syndrome precipitated by central but not peripheral hexamethonium”, Pharmacol. Biochem. Behav.
Malin, D.H., Lake, J.R., Upchurch, T.P., Shenoi, M., Rajan, N. and Schweinle, W.E. (1998) “Nicotine abstinence syndrome precipitated by the competitive nicotinic antagonist dihydro-β-erythroidine”, Pharmacol. Biochem. Behav.
Marcus, P. and Snyder, R. (1995) “Reduction of comorbid substance abuse with clozapine”, Am. J. Psychiatry
Marder, S.R., Wirshing, W.C. and Van Putten, T. (1991) “Durg treatment of schizophrenia: Overview of recent research”, Schizophr. Res.
Markou, A. and Koob, G.F. (1991) “Post-cocaine anhedonia: an animal model of cocaine withdrawal”, Neuropsychopharmacology
Markou, A. and Koob, G.F. (1992a) “Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations”, Physiol. Behav.
Markou, A. and Koob, G.F. (1992b) “Bromocriptine reverses the elevation in intracranial self-stimulation thresholds observed in a rat model of cocaine withdrawal”, Neuropsychopharmacology
Markou, A. and Koob, G.F. (1993) “Intracranial self-stimulation thresholds as a measure of reward”, In: Sahgal, A., eds, Behavioural Neuroscience, A Practical Approach, (Oxford University Press, New York) Vol. 2, pp 93–115.
Markou, A. and Paterson, N. (2001) “The role of α7 nicotinic receptors in nicotine self-administration and withdrawal in the rat”, Nicotine Tobacco Res., 361–373.
Markou, A., Hauger, R.L. and Koob, G.F. (1992) “Desmethylipramine attenuates cocaine withdrawal in rats”, Psychopharmacology
Markou, A., Kosten, T.R. and Koob, G.F. (1998) “Neurobiological similarities in depression and drug dependence: a self-medication hypothesis”, Neuropsychopharmacology
Masterson, E. and O'Shea, B. (1984), “Smoking and malignancy in schizophrenia”, Br. J. Psychiatry
Mauskopf, J.A., David, K., Grainger, D.L. and Gibson, P.J. (1999) “Annual health outcomes and treatment costs for schizophrenia populations”, J. Clin. Psychiatry
(Suppl. 19), 14–19.PubMed
McAskill, R., Mir, S. and Taylor, D. (1998) “Pindolol augmentation of antidepressant therapy”, Br. J. Psychiatry
McEvoy, J., Freudenreich, O., McGee, M., VanderZwaag, C., Levin, E. and Rose, J. (1995) “Clozapine decreases smoking in patients with chronic schizophrenia”, Biol. Psychiatry
McEvoy, J.P., Freudenreich, O. and Wilson, W.H. (1999) “Smoking and therapeutic response to clozapine in patients with schizophrenia”, Biol. Psychiatry
Meltzer, H.Y. (1999) “Outcome in schizophrenia: beyond symptom reduction”, J. Clin. Psychiatry
(Suppl. 3), 3–7.PubMed
Menza, M.A., Grossman, N., Van Horn, M., Cody, R. and Forman, N. (1991) “Smoking and movement disorders in psychiatric patients”, Biol. Psychiatry
Moller, H.J. (1998) “Novel antipsychotics and negative symptoms”, Int. Clin. Psychopharmacol.
(Suppl. 3), S43-S47.PubMed
Mueser, K.T., Yarnold, P.R., Levinson, D.F., Singh, H., Bellack, A.S., Kee, K., Morrison, R.L. and Yadalam, K.G. (1990) “Prevalence of substance abuse in schizophrenia: demographic and clinical correlates”, Schizophr. Bull.
Nunes, E.V., McGrath, P.J., Quitkin, F.M., Ocepek-Welikson, K., Stewart, J.W., Koenig, T., Wager, S. and Klein, D.F. (1995) “Imipramine treatment of cocaine abuse: possible boundaries of efficacy”, Drug Alcohol Depend.
Olincy, A., Young, D.A. and Freedman, R. (1997) “Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers”, Biol. Psychiatry
Parrott, A.C. (1993) “Cigarette smoking: effects upon self-rated stress and arousal over the day”, Addict. Behav.
Parsons, L.H., Smith, A.D. and Justice, Jr., J.B. (1991) “Basal extracellular dopamine is decreased in the rat nucleus accumbens during abstinence from chronic cocaine”, Synapse
Parsons, L.H., Koob, G.F. and Weiss, F. (1995) “Serotonin dysfunction in the nucleus accumbens of rats during with-drawal after unlimited access to intravenous cocaine”, J. Pharmacol. Exp. Ther.
Paterson, N.E., Myers, C. and Markou, A. (2000) “Effects of repeated withdrawal from continuous amphetamine administration on brain reward function”, Psychopharmacology
Patkar, A.A., Alexander, R.C., Lundy, A. and Certa, K.M. (1999) “Changing patterns of illicit substance use among schizophrenic patients: 1984–1996”, Am. J. Addict.
Phillips, A.G. and Fibiger, H.C. (1989) “Neuroanatomical basis of intracranial self-stimulation reward: untangling the Gordian knot”, In: Liebman, J.M. and Cooper, S.J., eds, The Neuropharmacological Basis of Reward (Clarendon Press, Oxford), pp 66–105.
Pomerleau, O., Adkins, D. and Pertschuk, M. (1978) “Predictors of outcome and recidivism in smoking cessation treatment”, Addict. Behav.
Risner, M.E. and Goldberg, S.R. (1983) “A comparison of nicotine and cocaine self-administration in the dog: fixed-ratio and progressive-ratio schedules of intravenous drug infusion”, J. Pharmacol. Exp. Ther.
Robbins, A.S. (1993) “Pharmacological approaches to smoking cessation”, Am. J. Prev. Med.
Robins, L.N., Regier, D.A., eds, (1991) Psychiatric Disorders in America: The Epidemiologic Catchment Area Study (The Free Press, New York).
Robins, L.N., Helzer, J.E., Weissman, M.M., Orvaschel, H., Gruenberg, E., Burke, Jr., J.D. and Regier, D.A. (1984) “Lifetime prevalence of specific psychiatric disorders in three sites”, Arch. Gen. Psychiatry
Robinson, D., Mayerhoff, D., Alvir, J., Cooper, T. and Lieberman, J. (1991) “Mood responses of remitted schizophrenics to methyl-phenidate infusion”, Psychopharmacology
Romero, L., Bell, N., Casanovas, J.M. and Artigas, F. (1996) “Two actions are better than one: avoiding self-inhibition of serotonergic neurones enhances the effects of serotonin uptake inhibitors”, Int. Clin. Psychopharmacol.
(Suppl. 4), 1–8.PubMedCrossRef
Rosenthal, R.N., Hellerstein, D.J. and Miner, C.R. (1994) “Positive and negative syndrome typology in schizophrenic patients with psychoactive substance use disorders”, Compr. Psychiatry
Rossetti, Z.L., Hmaidan, Y. and Gessa, G.L. (1992) “Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats”, Eur. J. Pharmacol.
Rounsaville, B.J., Anton, S.F., Carroll, K., Budde, D., Prusoff, B.A. and Gawin, F. (1991) “Psychiatric diagnoses of treatmentseeking cocaine abusers”, Arch. Gen. Psychiatry
Sandyk, R. (1993) “Cigarette smoking: Effects on cognitive functions and drug-induced parkinsonism in chronic schizophrenia”, Int. J. Neurosci.
Sanfilipo, M., Wolkin, A., Angrist, B., van Kammen, D.P., Duncan, E., Wieland, S., Cooper, T.B., Peselow, E.D. and Rotrosen, J. (1996) “Amphetamine and negative symptoms of schizophrenia”, Psychopharmacology
Satel, S.L., Price, L.H., Palumbo, J.M., McDougle, C.J., Krystal, J.H., Gawin, F., Charney, D.S., Heninger, G.R. and Kleber, H.D. (1991) “Clinical phenomenology and neurobiology of cocaine abstinence: a prospective inpatient study”, Am. J. Psychiatry
Schneier, F.R. and Siris, S.G. (1987) “A review of psychoactive substance use and abuse in schizophrenia: patterns of drug choice”, J. Nerv. Ment. Dis.
Schuckit, M.A., Tipp, J.E., Bergman, M., Reich, W., Hesselbrock, V.M. and Smith, T.L. (1997) “A comparison of induced and independent major depressive disorders in 2945 alcoholics”, Am. J. Psychiatry
Serper, M.R., Alpert, M., Richardson, N.A., Dickson, S., Allen, M.H. and Werner, A. (1995) “Clinical effects of recent cocaine use on patients with acute schizophrenia”, Am. J. Psychiatry
Sevy, S., Kay, S.R., Opler, L.A. and van Praag, H.M. (1990) “Significance of cocaine history in schizophrenia”, J. Nerv. Ment. Dis.
Shiffman, S.M. and Jarvik, M.E. (1976) “Smoking withdrawal symptoms in two weeks of abstinence”, Psychopharmacology
Slemmer, J.E., Martin, B.R. and Damaj, M.I. (2000) “Bupropion is a nicotinic antagonist”, J. Pharmacol. Exp. Ther.
Soni, S.D. and Brownlee, M. (1991) “Alcohol abuse in chronic schizophrenics: implications for management in the community”, Acta Psychiatr. Scand.
Stellar, J. and Stellar, E. (1985) The Neurobiology of Reward and Motivation (Springer, New York).
Stevens, S.S. (1951) “Mathematics measurement, and psychophysics”, In: Stevens, S., eds, Handbook of Experimental Psychology (Wiley, New York), pp 1–49.
Stolerman, I.P. and Jarvis, M.J. (1995) “The scientific case that nicotine is addictive”, Psychopharmacology
Tran, P.V., Hamilton, S.H., Kuntz, A.J., Potvin, J.H., Andersen, S.W., Beasley, Jr., C. and Tollefson, G.D. (1997) “Double-blind comparison of olanzapine verus risperidone in the treatment of schizophrenia and other psychotic disorders”, J. Clin. Pharmacol.
Waal-Manning, H.J. and de Hamel, F.A. (1978) “Smoking habit and psychometric scores: a community study”, Z.N. Med. J.
Watkins, S.S., Epping-Jordan, M.P., Koob, G.F. and Markou, A. (1999) “Blockade of nicotine self-administration with nicotinic antagonists in rats”, Pharmacol. Biochem. Behav.
Watkins, S.S., Koob, G.F. and Markou, A. (2000a) “Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal”, Nicotine Tobacco Res.
Watkins, S.S., Stinus, L., Koob, G.F. and Markou, A. (2000b) “Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects”, J. Pharmacol. Exp. Ther.
Weddington, W.W., Brown, B.S., Haertzen, C.A., Cone, E.J., Dax, E.M., Herning, R.I. and Michaelson, B.S. (1990) “Changes in mood, craving, and sleep during short-term abstinence reported by male cocaine addicts: a controlled, residential study”, Arch. Gen. Psychiatry
Weiss, F., Markou, A., Lorang, M.T. and Koob, G.F. (1992) “Basal dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-acess self-administration”, Brain Res.
West, R. and Gossop, M. (1994) “Overview: A comparison of withdrawal symptoms from different drug classes”, Addiction
West, R.J., Jarvis, M.J., Russell, M.A., Carruthers, M.E. and Feyerabend, C. (1984) “Effect of nicotine replacement on the cigarette withdrawal syndrome”, Br. J. Addict.
Wilkins, J.N. (1997) “Pharmacotherapy of schizophrenia patients with comorbid substance abuse”, Schizophr. Bull.
Wise, R.A. and Munn, E. (1993) “Effects of repeated amphetamine injections on lateral hypothalarnic brain stimulation reward and subsequent locomotion”, Behav Brain Res.
Wise, R.A. and Munn, E. (1995) “Withdrawal from chronic amphetamine elevates baseline intracranial self-stimulation thresholds”, Psychopharmacology
Wise, R.A., Bauco, P., Carlezon, Jr, W.A. and Trojniar, W. (1992) “Self-stimulation and drug reward mechanisms”, Ann. N.Y. Acad. Sci.
Wong, D.T., Bymaster, F.P. and Engleman, E.A. (1995) “Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication”, Life Sci.
Yassa, R., Lal, S., Korpassy, A. and Ally, J. (1987) “Nicotine exposure and tardive dyskinesia”, Biol. Psychiatry
Zanardi, R., Artigas, F., Franchini, L., Sforzini, L., Gasperini, M., Smeraldi, E. and Perez, J. (1997) “How long should pindolol be associated with paroxetine to improve the antidepressant response?”, J. Clin. Psychopharmacol.
Ziedonis, D.M. and Kosten, T.R. (1991) “Depression as a prognostic factor for pharmacological treatment of cocaine dependence”, Psychopharmacol. Bull.
Ziedonis, D., Richardson, T., Lee, E., Petrakis, I. and Kosten, T. (1992) “Adjunctive desipramine in the treatment of cocaine abusing schizophrenics”, Psychopharmacol. Bull.
Ziedonis, D.M., Kosten, T.R., Glazer, W.M. and Frances, R.J. (1994) “Nicotine dependence and schizophrenia”, Hosp. Community Psychiatry
Zimmet, S.V., Strous, R.D., Burgess, E.S., Kohnstamm, S. and Green, A.I. (2000) “Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: A retrospective survey”, J. Clin. Pharmacol.